Lunai Bioworks (LNAI) Q1 2026 earnings summary

Executive summary

• Achieved net income of $2.8M for Q3 2025, a significant improvement from a $44.2M net loss in Q3 2024, primarily due to the absence of prior year goodwill impairment and a gain from subsidiary bankruptcy.

• Operating expenses decreased 94% year-over-year, driven by lower goodwill impairment and reduced general and administrative costs.

• Completed the acquisition of BioSymetrics Inc. in April 2025, expanding AI-driven precision medicine capabilities.

• Deconsolidated Gedi Cube B.V. following its bankruptcy, resulting in a $12M gain.

Financial highlights

• Net income for Q3 2025 was $2.8M, compared to a net loss of $44.2M in Q3 2024.

• Operating expenses fell to $3.3M from $53.3M year-over-year, mainly due to a $47.6M goodwill impairment in the prior year.

• Cash increased to $624.8K as of September 30, 2025, up from $92.7K at June 30, 2025.

• Working capital deficit improved to $18.9M from $28.1M sequentially.

• Total assets were $7.0M and total liabilities $20.0M at quarter-end.

Outlook and guidance

• Management is focused on streamlining operations around AI-driven neurology and oncology diagnostics and therapeutic development.

• Additional funding is required to support ongoing operations and commercialization efforts; there is substantial doubt about the ability to continue as a going concern without new capital.

• Funding received in fiscal 2026 will be used for obligations, product commercialization, clinical development, and working capital.